Press releases Featured Mar 22, 2024 NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Mar 22, 2024 Mar 22, 2024 Mar 21, 2024 NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine Mar 21, 2024 Mar 21, 2024 Mar 1, 2024 NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences Mar 1, 2024 Mar 1, 2024 Jan 22, 2024 NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services Jan 22, 2024 Jan 22, 2024 Nov 15, 2023 NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing Nov 15, 2023 Nov 15, 2023 Oct 3, 2023 NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society Oct 3, 2023 Oct 3, 2023 Sep 26, 2023 NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Sep 26, 2023 Sep 26, 2023 Sep 8, 2023 NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association Sep 8, 2023 Sep 8, 2023 Jun 20, 2023 NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Jun 20, 2023 Jun 20, 2023 Jun 9, 2023 NMD Pharma to Present Results from the Charcot-Marie-Tooth ESTABLISH Study at the Peripheral Nerve Society Annual Meeting Jun 9, 2023 Jun 9, 2023